

Pernicious Anemia

Mario García-Carrasco, Mario Jiménez-Hernández, Claudia Mendoza-Pinto, Alejandro Ruiz-Argüelles and Salvador Fuentes-Alexandro

Abstract Pernicious anemia (PA) is the most common manifestation of vitamin B₁₂ deficiency, in which an autoimmune pathogenesis is supported by (a) the presence of mononuclear-cell infiltration into gastric mucosa with loss of parietal cells, (b) autoantibodies to parietal cells and intrinsic factor, (c) autoreactive T cells, (d) regeneration of parietal cells after therapy with corticosteroids or immunosuppressive drugs, (e) familial predisposition and (f) association with other autoimmune diseases. The progression of the chronic atrophic gastritis to gastric atrophy and clinical anemia is likely to span 20 to 30 years. The presence of serum antibodies to gastric parietal-cells predicts autoimmune gastritis. Immune suppression with corticosteroids or azathioprine appears to be the best treatment in early stages of the disease.

Keywords Pernicious anemia · vitamin B₁₂ deficiency · type A gastritis

Pernicious anemia (PA) also known as *Biermer's anaemia*, *Addison's anaemia* or *Addison-Biermer anaemia*, is a form of megaloblastic anemia due to vitamin B₁₂ (Cbl) deficiency; it is an autoimmune disease resulting from antibodies against intrinsic factor (IF) and gastric parietal cells (1); gastric atrophy probably resulting from immune destruction of the acid and pepsin-secreting portion of the gastric mucosa.; PA is considered as a chronic illness in which there is impaired absorption of vitamin B₁₂ in the terminal ileum because of a lack of IF (secreted by the parietal cells of the gastric mucosa) (2); its usual course is slowly progressive and is the most common cause of vitamin B₁₂ deficiency and, at the end stage, of the type A atrophic gastritis influencing the fundus and body of the stomach (3).

than was previously recognized. Accordingly, reports of small case series of Chinese PA patients have emerged: Wun Chan et al. (5) recently found that 224 of 296 (76%) Chinese with megaloblastic anemia had PA. In fact the incidence is increasing in women and older adults because the diagnosis is unusual before 35 years of age, although typical pernicious anemia can be seen in children under 10 years of age (juvenile pernicious anemia) (3) and the overall prevalence of undiagnosed PA over age 60 years of age is 1.9% (4). In general, the prevalence is 80 cases per 100,000 individuals and the prevalence is highest in women (2.7%), particularly in black women (4.3%) and is less common in southern Europeans and Asians (6).

Epidemiology

Traditionally, pernicious anemia was believed to occur predominantly in people of northern European descent as well as in older populations because multiple epidemiological studies have shown that the average age of onset of pernicious anemia is greater than 60 years, with an increasing frequency with advancing age. Moreover, Carmel et al. (4) in a population survey found that 1.9% of persons more than 60 years of age have undiagnosed pernicious anemia. Nowadays, it has become apparent that the occurrence of PA in all racial and ethnic groups is more common

History

Pernicious anemia was first described in 1849 by the English physician Thomas Addison; later on, Austin Flint in 1869 linked the anemia with alterations of the stomach. (7) The name "pernicious anemia" was coined in 1872 by the German physician Anton Biermer. The studies of George H. Whipple on the effects of feeding liver in anemia followed by those of George R. Minot and William P. Murphy on the effects of feeding liver specifically in pernicious anemia led to the cure of pernicious anemia and to their receiving the Nobel Prize in 1934. As a result, it was suggested that the anemia was caused by lack of an

extrinsic factor found in liver that was vitamin B-12 and an intrinsic factor in gastric secretion. Afterward, a serum inhibitor factor of intrinsic factor and autoantibodies to parietal cells were discovered (8) giving an immunological explanation of the underlying gastritis that caused pernicious anemia. Also in the 1950s and 1960s, the Schilling test became established.

Pathogenesis

A genetic predisposition to PA is suggested by clustering of the disease and of gastric autoantibodies in families, and by the association of the disease and gastric autoantibodies with the autoimmune endocrinopathies. About 20% of the relatives of patients with PA have PA. These relatives, especially first-degree female relatives, also have a higher frequency of gastric autoantibodies than normal. Recently, Junca et al. (8) detected early abnormalities in gastric function in first-degree relatives of patients with PA. About 23% of these relatives had parietal-cell antibodies. The disease is associated with HLA types A2, A3, A7, and B12 and with blood group A (9). The pathological process associated with type A gastritis appears to be directed toward the gastric parietal cells, shown by pathologic lesions restricted to parietal cells and the presence of autoantibodies to parietal cells and to their secretory product, intrinsic factor, in the serum and gastric juice. Evidence has shown that H^+/K^+ -ATPase is the antigen recognized by parietal-cell autoantibodies (10). This enzyme has a highly conserved catalytic (α) subunit that is phosphorylated during reaction cycles. Gastric H^+/K^+ -ATPase is responsible for secretion of hydrogen ions by parietal cells in exchange for potassium ions. Autoantibodies to parietal cells bind to both the 100-kd catalytic (α) subunit and the 60-to-90-kd glycoprotein (β) subunit of gastric H^+/K^+ -ATPase. Although parietal-cell autoantibodies can fix complement and lyse parietal cells in vitro, it is unlikely that these autoantibodies are pathogenic in vivo, because gastric H^+/K^+ -ATPase is not accessible to circulating antibodies. The importance, if any, of an early observation that passive transfer of parietal cell autoantibodies to rats resulted in reduction in parietal-cell mass without an inflammatory response is therefore uncertain. This particular finding could reflect that cell loss is due to antibody-triggered apoptosis, as has been forwarded for other pathophysiological conditions (11). A report describing autoantibodies that bind to the gastrin receptor was not confirmed. The results of studies showing reactivity of parietal-cell autoantibodies with the surface membranes of parietal cell in vitro may be explained by the loss of cell polarity after cellular dissociation (12). Pathogenic $CD4^+$ T cells are reactive to the parietal cell autoantigen, H^+/K^+ ATPase, and are controlled by $CD4^+CD25^+$ T cells in an immunosuppressive cytokine-independent

manner. Comparison of $CD4^+CD25^+$ T cell-mediated suppression in other autoimmune models shows inconsistencies with respect to requirements of cytokines for immunosuppression. More recent data, however, indicate that the evidence for requirement of IL-10 and TGF- β could be due to the complex nature of the T cells causing the disease, as well as the role of induced regulatory T-cell populations. Evidence from this model indicates that immune responses must be initiated and then $CD4^+CD25^+$ T cells are recruited to control the quality of the immune response (10, 12). Finally, anemia, the principal feature of PA is caused by malabsorption of vitamin B_{12} in the terminal ileum due to intrinsic-factor deficiency.

Clinical Manifestations

The classic triad of weakness, sore tongue, and paresthesias may be elicited but usually is not the chief symptom complex, because the onset of PA is insidious and unclear and progresses slowly. Generally, the anemia is often well tolerated in this disease and many patients are ambulatory. The median age at diagnosis is 60 years; however, childhood PA has been reported associated with genetic failure to secrete intrinsic factor or the secretion of a defective intrinsic factor (13). Symptoms of anemia are the usual presentation, but asymptomatic patients can be identified by routine hematologic investigation. Generally, the presentation of pernicious anemia resembles that of any other form of anemia. Mainly, neurological complications secondary vitamin B_{12} deficiency are developed which may cause peripheral neuropathy (paresthesias and numbness) and lesions in the posterior (loss of vibration and position sense, sensory ataxia) and lateral columns (limbs weakness, spasticity, and extensor plantar response) of the spinal cord and in the cerebrum. These lesions progress from demyelination to axonal degeneration and eventual neuronal death (14). Megaloblastic madness is less common and can be manifested by delusions, hallucinations, outbursts, and paranoid schizophrenic ideation. Identifying the cause is important because significant reversal of these symptoms and findings can occur with vitamin B-12 administration. Also, patients with PA may develop several abnormalities of the digestive tract such as atrophic glossitis characterized by smooth and beefy, tongue megaloblastosis of the epithelial cells of the small intestine that results in diarrhea and malabsorption. Intestinal metaplasia is a risk factor for adenocarcinoma (15). Achlorhydria and bacterial overgrowth may also lead to the formation of carcinogenic nitrosoamines. The cardiovascular system is also affected; cardiac output is usually increased with hematocrit less than 20%, and the heart rate accelerates; therefore, in patients with preexisting heart disease, coronary insufficiency and congestive heart failure can occur. On the contrary, PA has been associated with common

TABLE 94.1. Clinical manifestation of PA.

Clinical Manifestation	Prevalence %
Anemia	30–60
Neurological complications	10–28
Peripheral neuropathy	0.6
Degeneration of cord	2.8
Dementia	5
Gastrointestinal complication	15
Glositis	1–3
Gastric carcinoma	

variable immunodeficiency and low serum immunoglobulin concentrations. Prevalence of clinical manifestations is shown in Table 94.1. PA may be associated with other autoimmune diseases such as autoimmune thyroiditis, insulin-dependent diabetes mellitus, Addison's disease, primary ovarian failure, primary hypoparathyroidism, Grave's disease, vitiligo, myasthenia gravis, and the Lambert-Eaton syndrome.

Pathological Features

Chronic atrophic gastritis is recognized macroscopically by loss of gastric mucosal folds and thinning of the gastric mucosa. It can be classified into two types according to whether the lesion affects the gastric antrum. Type A (autoimmune) gastritis involves the fundus and the body of the stomach and spares the antrum. It is associated with PA, autoantibodies to gastric parietal cells and to intrinsic factor, achlorhydria, initial low serum gastrin concentrations, that later result in hyperplasia of gastrin-producing cells. Type B gastritis is usually associated with *Helicobacter pylori* infection (10). The most common lesion in gastric-biopsy specimens from PA patients are mononuclear cellular infiltrates in the submucosa extending into the lamina propria between the gastric glands; extension of the cellular infiltrate into the mucosa is accompanied by degenerative changes in parietal cells and zymogenic cells. The cellular infiltrate includes plasma cells and T cells (16). Thereafter, the mucosa becomes atrophic, containing few pepsin-secreting and parietal cells, and then intestinal metaplasia is established. The chronic atrophic gastritis in PA is also associated with an increased risk of intestinal-type gastric cancer and gastric carcinoid tumors. The latter are presumably due to prolonged achlorhydria resulting from parietal-cell loss, compensatory hypergastrinemia, and argyrophilic cell hyperplasia. The bone marrow biopsy and aspirate usually shows that erythroid precursors are large and often oval. The nucleus is large and contains coarse motley chromatin clumps, having a checkerboard appearance. Nucleoli are visible in the more immature erythroid precursors. Giant metamyelocytes and bands are present, and the mature neutrophils and eosinophils are hypersegmented. The bone marrow histology is similar

in both folic acid and Cbl deficiency. The megaloblastic changes due to Cbl deficiency can be reversed by pharmacological doses of folic acid but not otherwise. (17).

Hematologic Features

Laboratory abnormalities found in PA with established megaloblastic anemia are summarized in Table 94.2. The most important laboratory finding observed in PA is erythrocytic macrocytosis which is obvious when the mean cell volume (MCV) is greater than 100 fL (1, 17). The MCV and mean corpuscular hemoglobin (MCH) are increased, with a mean corpuscular hemoglobin concentration (MCHC) within the reference range. In addition, the peripheral blood usually shows a mild leukopenia and thrombocytopenia or pancytopenia, which parallel the severity of the anemia because vitamin B12 deficiency affects all hematopoietic cell lineages (10). Examination of the marrow is not indicated if the diagnosis is unequivocal; the earliest sign of megaloblastosis reflected in the peripheral blood smear is hypersegmentation of the polymorphonuclear leukocytes followed by the appearance of oval macrocytes, and anisopoikilocytosis (17).

Serological and Biochemical Features

Diagnosis of PA is supported by measuring blood levels of Cobalamin (Cbl) and folate; Cbl is low in most but not all patients with cobalamin deficiency. Patients with vitamin B12 deficiency will have serum levels <170 pg/mL, with symptomatic patients usually having levels <100 pg/mL. The diagnosis is best confirmed by finding an elevated level of serum methylmalonic acid (>1000 nmol/L); in fact, two metabolic markers, plasma methylmalonic acid (MMA) and plasma total homocysteine (tHC), are generally considered as more sensitive indicators of vitamin B12 status than plasma cobalamin levels. MMA and tHC are elevated in vitamin B12 deficiency (17). Normal MMA and

TABLE 94.2. Hematological findings in PA patients.

Peripheral blood
Macrocytosis with hypersegmented polymorphonuclear leukocytes.
Anemia
Leukopenia
Thrombocytopenia or
Pancytopenia
Bone marrow
Megaloblasts
Large myeloid precursors ("giant metamyelocytes")
Low serum vitamin B ₁₂ concentrations
Normal serum folate concentrations
Positive Schilling test
Low serum holotranscobalamin concentrations

TABLE 94.3. Prevalence of autoantibodies to gastric parietal cells in several situations.

Patients with pernicious anemia	90%
Patients with simple atrophic gastritis	60%
Nonanemic first-degree relatives of patients with PA	30%
Normal subjects in the third decade	2.5%
Normal subjects in the eight decade	9.6%

homocysteine levels rule out cobalamin deficiency with 100% confidence, and normal homocysteine levels suggest that megaloblastic anemia is not caused by folate deficiency, since only tHC is elevated in folic acid deficiency (18). However an increased concentration of plasma methylmalonic acid (P-MMA) does not predict clinical manifestations of vitamin B₁₂ deficiency and should not be used as the only marker for diagnosis of B₁₂ deficiency. A Schilling test will confirm that vitamin B₁₂ deficiency is the results of intestinal malabsorption due to intrinsic-factor deficiency. The Shilling test assay for cobalamin absorption consists of measuring urinary radioactivity after an oral dose of radioactive cobalamin is given: Absorption is low in PA, and it increases if radioactive vitamin B₁₂ is administrated along with intrinsic factor (17). In patients with PA, serum antibodies that recognize the H⁺/K⁺-ATPase occur. Table 94.3 shows the prevalence of autoantibodies in PA. Antiparietal cell antibodies also occur in a significant percentage of patients with thyroid disease (1), and conversely, patients with PA have a higher than expected prevalence of antibodies against thyroid epithelium, lymphocytes, and renal collecting duct cells. Serum antibodies to gastric parietal cells can be detected by indirect immunofluorescence with unfixed, air-dried, frozen sections of mouse stomach in which the antibodies stain parietal cells. Antibodies to intrinsic factor ("type I" or "blocking," antibodies) or the intrinsic factor-cobalamin complex ("type II" or "binding," antibodies) are highly specific to PA patients. Type I autoantibodies are demonstrable in the serum of about 70% of patients with PA. Type II autoantibodies are found in the serum of about 35–40% of patients, and rarely occur in the absence of type I antibodies. Both types of autoantibodies can be detected more frequently in gastric juice than in serum (16).

Diagnostic Criteria

There are no diagnostic criteria for PA; however the presence of hematologic disorders, such as megaloblastic anemia, with positive Schilling test and type A chronic atrophic gastritis with loss of gastric parietal cells can support the diagnosis.

Prognosis

PA is a silent disease until its advanced or end stage. The prognosis depends of the stage of the disease when the diagnosis is made. Neurological complications may not be reversed even when the treatment is begun. On the contrary, if gastric cancer or gastric carcinoid tumors are developed, the prognosis will also depend on the early diagnosis and treatment. Because PA is associated with achlorhydria there is a 3-fold likelihood of developing gastric carcinoma; therefore periodic endoscopy is recommended approximately every 5 years, even in asymptomatic cases, to rule out gastric polyps or gastric carcinoma.

Predicting Role of Autoantibodies

The presence of serum gastric parietal cells predicts autoimmune gastritis. Anti parietal cells and anti-intrinsic factor antibodies are rarely measured in individuals with megaloblastic anemia, even though the anti-intrinsic factor antibodies in particular could be of considerable diagnostic value. Anti-intrinsic factor antibody is highly specific for PA (although its sensitivity is only modest), and its presence in megaloblastic anemia makes the diagnosis of PA almost certain.

Therapeutic Management

The first standard treatment widely used was a regular monthly intramuscular injection of at least 1 mg of vitamin B₁₂ to correct the vitamin deficiency (4). Therapeutic management is summarized in Table 94.4. However, nowadays there are different proposed schedules:

- Therapy consisting of five to six intramuscular injections of hydroxocobalamin (1 mg each) over a 3-week period. Patients are then given 1 mg intramuscularly every 3 months for life (19). This regimen corrects the hematological abnormalities and replaces B₁₂ stores.
- Therapy consisting of intramuscular injection of hydroxocobalamin 1 mg three times a week for two weeks and then once every 3 months for life. Daily dosing is given initially if there is neurological involvement (20).

These two treatments correct the anemia and may correct the neurological complications if given soon after their onset.

There is little evidence of a satisfactory hematological, biochemical, and clinical short-term response for oral B₁₂ replacement in some randomized controlled trials. The evidence derived from limited studies suggests that high oral doses of B₁₂ (1000 and 2000 mg daily) could be as effective as intramuscular administration in achieving hematological and neurological responses (21). Accordingly, high doses of oral vitamin B₁₂ (1000 mg) initially

TABLE 94.4. Pharmacological treatment of pernicious anemia.

	Acute treatment	Dose	Duration	Maintenance	Dose	Duration
A	Hydroxocobalamin	100 mcg IV every other day	3 weeks	Hydroxocobalamin	100 mcg IV	Every 3 months for life
B	Hydroxocobalamin	100 mcg IV 3 times a week	2 weeks	Hydroxocobalamin	100 mcg IV	once every 3 months for life
C	Hydroxocobalamin	1000–2000 mg VO daily	120 days	Not available data		
D	Hydroxocobalamin	1000 mg VO		Not available data		

daily, thereafter weekly, and then monthly, are as effective as intramuscular vitamin B12 (22).

In the meantime, for newly diagnosed patients with vitamin B12 deficiency secondary to pernicious anaemia, who have an intact terminal ileum, an initial intramuscular dose of vitamin B12 followed by a trial of oral replacement may be considered (21). This recommendation is based on the observation that about 1% of vitamin B12 is absorbed by mass action in the absence of intrinsic factor.

A further large, pragmatic trial in primary care is needed to determine whether oral vitamin B12 is effective in patients with pernicious anaemia in primary care settings, but this therapy should not be used in hospitalized/critical patients.

Precautions in the therapy replacement of B12 deficiency should be considered:

- Administration of folic acid in a patient with vitamin B12 deficiency may induce a hematological response but will worsen any neurological symptoms, and can actually precipitate subacute combined degeneration of the cord (19).
- Patients with pernicious anaemia should also be given oral iron, because most will soon exhaust their iron stores (20).

References

1. Kumar V. Pernicious anemia. *MLO Med Lab Obs* 2007 Feb;39(2):28, 30–1.
2. Andres E, Federici L, Affenberger S, Vidal-Alaball J, Loukili NH, Zimmer J, Kaltenbach G. B12 deficiency: A look beyond pernicious anemia. *J Fam Pract* 2007 Jul; 56(7): 537–42.
3. Toh BH, Van Dreil IR, Gleeson PA. Pernicious anemia. *N Engl J Med* 1997;337:1441–48.
4. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. *Arch Intern Med* 1996;156:1097.
5. Wun Chan JC, Yu liu HS, Sang Kho BC, Yin Sim JP, Hang Lau TK, Luk YW, Chu RW, Fung Cheung FM, Tat Choi FP, Kwan Ma ES. Pernicious anemia in Chinese. *Medicine* 2006; 85:129–38.
6. Castle WB. Development of knowledge concerning the gastritis intrinsic factor and its relation to pernicious anemia. *N Engl J Med* 1953;249:603–14.
7. Taylor KB. Inhibition of intrinsic factor by pernicious anemia sera. *Lancet* 1959;2:1347–52.
8. Junca J, de Soria PL, Granada ML, Flores A, Márquez E. Detection of early abnormalities in gastric function in first-degree relatives of patients with pernicious anemia. *Eur J Haematol* 2006;77:518–22.
9. Ungar B, Matthews JD, Tait BD, Cowling DC. HLA-DR patterns in pernicious anaemia. *Br Med J* 1981;282:768.
10. Ban-Hock, van Driel, Ian R, Gleeson, Paul A. Mechanisms of Disease: Pernicious Anemia. *N Engl J Med* 1997 Nov 13; 337(20):1441–8.
11. Ruiz-Argüelles A, Jiménez-Brito G, Reyes-Izquierdo P, Pérez-Romano B, Sánchez-Sosa S. Apoptosis of melanocytes in vitiligo results from antibody penetration. *J Autoimmun*; 2007;29:281–6.
12. McHughs RS. Autoimmune gastritis is a well-defined autoimmune disease model for the study of the CD4+ CD25+ T cell-mediated suppression. *Curr Top Microbiol Immunol* 2005;293:153–77.
13. McIntyre OR, Sullivan LW, Jeffries GH, Silver RH. Pernicious anemia in childhood. *N Engl J Med* 1965;272:981–86.
14. Stabler SP, Allen RH, Savage DG, Lindenbaum J. Clinical spectrum and diagnosis of cobalamin deficiency. *Blood* 1990;76:871–81.
15. Hsing AW, Hansson L-E, McLaughlin JK, et al. Pernicious anemia and subsequent cancer: A population-based cohort study. *Cancer* 1993;71:745–50.
16. Kaye MD, Whorweel PJ, Wright R. Gastric mucosal lymphocyte subpopulations in pernicious anemia and in normal stomach. *Clin Immunol Immunopathol* 1983; 28: 431–40.
17. Anne-Mette Hvas et al. Diagnosis and treatment of vitamin B₁₂ deficiency: An update. *Haematologica* 2006;91:1506–12.
18. Goringe A, Ellis R, McDowell I, Vidal-Alaball J, Jenkins C, Butler C, et al. The limited value of methylmalonic acid, homocysteine and holotranscobalamin in the diagnosis of early B12 deficiency. *Haematologica* 2006;91:231–4.
19. Provan D, Weatherall D. Red cells II: Acquired anaemias and polycythaemia. *Lancet* 2000;355:1260–8.
20. Ballinger A. Gastroenterology and Anaemia. *Medicine* 2007;35(3):142–6.
21. Butler CC, Vidal-Alaball J, Cannings-John R, McCaddon A, Hood K, Papaioannou A, McDowell I, Goringe A. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: A systematic review of randomized controlled trials. *Fam Pract* 2006;23(3):279–85.
22. Bolaman Z, Kadikoylu G, Yukselen V, Yavasoglu I, Barutca S, Senturk T. Oral versus intramuscular cobalamin treatment in megaloblastic anemia: A single-center, prospective, randomized, open-label study. *Clin Ther* 2003;25:3124–34.